Oral liquid in situ gelling methylcellulose/alginate formulations for sustained drug delivery to dysphagic patients
- PMID: 22283456
- DOI: 10.3109/03639045.2011.634809
Oral liquid in situ gelling methylcellulose/alginate formulations for sustained drug delivery to dysphagic patients
Abstract
Background: Elderly patients with swallowing dysfunction may benefit from the oral administration of liquid dosage forms with in situ gelling properties.
Aim: We have designed in situ gelling liquid dosage formulations composed of mixtures of methylcellulose, which has thermally reversible gelation properties and sodium alginate, the gelation of which is ion-responsive, with suitable rheological characteristics for ease of administration to dysphagic patients and suitable integrity in the stomach to achieve a sustained release of drug.
Method: The rheological and gelation characteristics of solutions containing methylcellulose (2.0%) and sodium alginate (0.25-1.0%) were assessed for their suitability for administration to dysphagic patients. The gel strength and in vitro and in vivo release characteristics of gels formed by selected formulations were compared using paracetamol as a model drug.
Results: Mixtures of 2.0% methylcellulose and 0.5% alginate containing 20% d-sorbitol were of suitable viscosity for ease of swallowing by dysphagic patients and formed gels at temperatures between ambient and body temperature allowing administration in liquid form and in situ gelation in the stomach. In vitro release of paracetamol from 2.0% methylcellulose/0.5% alginate gels was diffusion-controlled at pH 1.2 and 6.8. Measurement of plasma levels of paracetamol after oral administration to rats of a 2.0% methylcellulose/0.5% alginate formulation showed improved sustained release compared to that from 2.0% methylcellulose and 0.5% alginate solutions and from an aqueous solution of paracetamol.
Conclusions: Solutions of mixtures of methylcellulose and alginate in appropriate proportions are of suitable consistency for administration to dysphagic patients and form gels in situ with sustained release characteristics.
Comment in
- Dysphagia. 2013 Jun;28(2):271-7
Similar articles
-
In situ gelling xyloglucan/alginate liquid formulation for oral sustained drug delivery to dysphagic patients.Drug Dev Ind Pharm. 2010 Apr;36(4):449-55. doi: 10.3109/03639040903244480. Drug Dev Ind Pharm. 2010. PMID: 19788404
-
In situ gelling formulation based on methylcellulose/pectin system for oral-sustained drug delivery to dysphagic patients.Drug Dev Ind Pharm. 2011 Jul;37(7):790-7. doi: 10.3109/03639045.2010.541465. Epub 2011 Mar 15. Drug Dev Ind Pharm. 2011. PMID: 21405940
-
Development of modified in situ gelling oral liquid sustained release formulation of dextromethorphan.Drug Dev Ind Pharm. 2012 Aug;38(8):971-8. doi: 10.3109/03639045.2011.634811. Epub 2011 Nov 18. Drug Dev Ind Pharm. 2012. PMID: 22092113
-
Phase transition system: novel oral in-situ gel.Curr Drug Deliv. 2008 Oct;5(4):282-9. doi: 10.2174/156720108785914952. Curr Drug Deliv. 2008. PMID: 18855597 Review.
-
Alginate drug delivery systems: application in context of pharmaceutical and biomedical research.Drug Dev Ind Pharm. 2014 Dec;40(12):1576-84. doi: 10.3109/03639045.2014.917657. Epub 2014 Aug 11. Drug Dev Ind Pharm. 2014. PMID: 25109399 Review.
Cited by
-
Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug.Drug Deliv. 2018 Nov;25(1):1161-1174. doi: 10.1080/10717544.2018.1474969. Drug Deliv. 2018. PMID: 29792353 Free PMC article.
-
Risedronate-Loaded Macroporous Gel Foam Enriched with Nanohydroxyapatite: Preparation, Characterization, and Osteogenic Activity Evaluation Using Saos-2 Cells.AAPS PharmSciTech. 2019 Feb 8;20(3):104. doi: 10.1208/s12249-019-1292-4. AAPS PharmSciTech. 2019. Retraction in: AAPS PharmSciTech. 2022 Aug 16;23(6):227. doi: 10.1208/s12249-022-02383-w. PMID: 30737611 Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical